The Food and Drug Administration (FDA) has given Pfizer rapid approval for the use of Elrexfio, which is a subcutaneous treatment for those suffering from resistant multiple myeloma. It is a severe and, until now, incurable form of blood cancer.
Elrexfio is a treatment for adults with myeloma who have had a relapse after having received at least four previous treatment regimens, according to the company’s announcement.
The FDA’s approval comes following research that revealed “significant reactions” in patients who received the therapy, as per Pfizer.
The study also indicates that findings show that patients taking multiple treatments in addition to the previous ones had a 5-8% response following treatment with Elrexfio. The rate was also high, with an estimated 82% sustaining the response at least for nine months.
Elrexfio therapy, which arrives “ready to utilize,” is injected under the skin. It is a maturation antigen from B cells that is responsible for producing antigen immunoglobins (also called antibodies) as well as aiding in fighting myeloma cell lines.
Multiple myeloma is a deadly and inoperable blood cancer that develops within the bone marrow.
“With notable responses within the patients who suffer from high-refractory diseases, we believe that Elrexfio could become the standard of treatment for patients with multiple myeloma.” Angela Hwang, chief commercial officer and vice president of Pfizer’s global biopharmaceutical companies, issued a statement. Pfizer.
The document warns that the most frequently reported side effects from treatment with this medication are fatigue, cytokine release syndrome, and injection site reactions. diarrhea, upper respiratory tract infections, muscle pain, diminished appetite, pneumonia, vomiting, rash, and an increase in temperature.
Multiple myeloma (MM) is the second-most common form of blood cancer. It has over 35,000 cases diagnosed each year across the US and 176,000 cases worldwide.